These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26028322)

  • 1. Assessment of the Anticoagulation Activity of Apixaban--Reply.
    Silvain J
    Circ J; 2015; 79(7):1642. PubMed ID: 26028322
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessment of the Anticoagulation Activity of Apixaban.
    Gonçalves LR; Araújo F
    Circ J; 2015; 79(7):1641. PubMed ID: 26028321
    [No Abstract]   [Full Text] [Related]  

  • 3. Measuring and reversing the effect of non-vitamin K antagonist oral anticoagulants (NOACs).
    Silvain J; Hauguel M; Kerneis M; Collet JP; Montalescot G;
    Circ J; 2015; 79(2):289-91. PubMed ID: 25744745
    [No Abstract]   [Full Text] [Related]  

  • 4. Reversal of rivaroxaban-induced alterations on hemostasis by different coagulation factor concentrates – in vitro studies with steady and circulating human blood.
    Escolar G; Arellano-Rodrigo E; Lopez-Vilchez I; Molina P; Sanchis J; Reverter JC; Carne X; Cid J; Villalta J; Tassies D; Galan AM; Diaz-Ricart M
    Circ J; 2015; 79(2):331-8. PubMed ID: 25482382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples.
    Bonar R; Favaloro EJ; Mohammed S; Ahuja M; Pasalic L; Sioufi J; Marsden K
    Pathology; 2016 Jan; 48(1):60-71. PubMed ID: 27020211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment.
    Den Uijl I; Mauser-Bunschoten EP; Roosendaal G; Schutgens R; Fischer K
    Haemophilia; 2009 Nov; 15(6):1215-8. PubMed ID: 19686467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of bypass surgery on coagulation-sensitive clotting factors.
    Woods JE; Kirklin JW; Owen CA; Thompson JH; Taswell HF
    Mayo Clin Proc; 1967 Nov; 42(11):724-35. PubMed ID: 6053800
    [No Abstract]   [Full Text] [Related]  

  • 8. Serial urological interventions including circumcision in a hemophilic child with inhibitors.
    Leblebisatan G; Saşmaz I; Antmen B; Klnç Y; Aridoğan IA
    Blood Coagul Fibrinolysis; 2011 Sep; 22(6):547-8. PubMed ID: 21519231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinants in thrombosis and hemostasis: from basic research to clinical therapy.
    Lippi G; Favaloro EJ
    Semin Thromb Hemost; 2010 Jul; 36(5):471-6. PubMed ID: 20632244
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effect of blood factors on the myosin content of cultured vascular smooth muscle cells].
    Melzig M; Teuscher E
    Acta Histochem; 1983; 73(2):289-91. PubMed ID: 6421075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haemostatic response to factor VIII administration in patients with haemophilia A measured by thrombin generation and correlation with factor concentrate use.
    Hugenholtz GC; Luddington R; Baglin T
    Haemophilia; 2016 Jan; 22(1):e42-5. PubMed ID: 26388112
    [No Abstract]   [Full Text] [Related]  

  • 12. Study of thrombin-coagulase.
    Soulier JP; Prou-Wartelle O
    Thromb Diath Haemorrh; 1967 May; 17(3-4):321-34. PubMed ID: 5589292
    [No Abstract]   [Full Text] [Related]  

  • 13. Bleeding and the new anticoagulants: strategies and concerns.
    Samama CM; Levy JH
    Anesthesiology; 2015 Feb; 122(2):236-7. PubMed ID: 25437499
    [No Abstract]   [Full Text] [Related]  

  • 14. Pre-analytical issues in the measurement of circulating microparticles: current recommendations and pending questions.
    Mullier F; Bailly N; Chatelain C; Chatelain B; Dogné JM
    J Thromb Haemost; 2013 Apr; 11(4):693-6. PubMed ID: 23410207
    [No Abstract]   [Full Text] [Related]  

  • 15. Association rate constants rationalise the pharmacodynamics of apixaban and rivaroxaban.
    Jourdi G; Siguret V; Martin AC; Golmard JL; Godier A; Samama CM; Gaussem P; Gouin-Thibault I; Le Bonniec B
    Thromb Haemost; 2015 Jul; 114(1):78-86. PubMed ID: 25761505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factor VIII-mediated global hemostasis in the absence of von Willebrand factor.
    Takeyama M; Kasuda S; Sakurai Y; Shima M; Takeda T; Omura S; Naka H; Yoshioka A
    Int J Hematol; 2007 Jun; 85(5):397-402. PubMed ID: 17562614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate.
    Barco S; Whitney Cheung Y; Coppens M; Hutten BA; Meijers JC; Middeldorp S
    Br J Haematol; 2016 Jan; 172(2):255-61. PubMed ID: 26488126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
    Perzborn E; Heitmeier S; Laux V; Buchmüller A
    Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclic peptide analogs of 558-565 epitope of A2 subunit of Factor VIII prolong aPTT. Toward a novel synthesis of anticoagulants.
    Anastasopoulos C; Sarigiannis Y; Stavropoulos G
    Amino Acids; 2014 Apr; 46(4):1087-96. PubMed ID: 24464027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prothrombin Time Tests for the Monitoring of Direct Oral Anticoagulants and Their Evaluation as Indicators of the Reversal Effect.
    Nagakari K; Emmi M; Iba T
    Clin Appl Thromb Hemost; 2017 Sep; 23(6):677-684. PubMed ID: 26984934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.